Hepatic Steatosis and Pituitary Gland Failure, Evaluation by Nuclear Magnetic Resonance (NMR) Imaging
Not Applicable
Completed
- Conditions
- Hepatic SteatosisPituitary Gland Failure
- Registration Number
- NCT02814240
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Brief Summary
The investigator put forward the hypothesis that liver fat mass in patients with pituitary gland failure is greater than that in a control population. Failure of the anterior pituitary and more particularly impaired production of growth hormone (GH) could be the principal mechanism responsible for increased liver fat mass in these patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
- Patients who have provided consent
- Patients over 18 years
- Patients with pituitary disease (Pituitary adenoma, anterior pituitary failure, craniopharyngioma, empty sella syndrome, hypophysitis, infiltration of the stalk) requiring Magnetic Resonance Imaging (MRI) of the pituitary.
Exclusion Criteria
- Persons without national health insurance
- Pacemaker (Contra-Indication for MRI)
- Alcohol consumption greater than 4 glasses a day
- Any treatment able to increase liver fat content (glitazones, systemic corticoids, immunosuppressants) are forbidden
- Presence of metallic implants (Contra-Indication for MRI)
- Claustrophobia
- Adult under guardianship
- Pregnant or breast-feeding women
- Patients with a liver disease other than non-alcoholic steatosis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Measurement of liver fat mass by Magnetic Resonance Imaging (MRI) Measured at Day 0
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link GH deficiency to increased hepatic steatosis in pituitary failure patients?
How does NMR imaging compare to FibroScan in quantifying liver fat in hypopituitarism populations?
Are there specific biomarkers for predicting liver fat accumulation in patients with anterior pituitary failure?
What adverse events are associated with GH replacement therapy in hypopituitarism and hepatic steatosis?
How do combination therapies involving GH and lipid-lowering agents impact liver fat in pituitary failure patients?
Trial Locations
- Locations (1)
CHU Dijon Bourgogne
🇫🇷Dijon, France
CHU Dijon Bourgogne🇫🇷Dijon, France